Get started

Alzheimersdisease

Alzheimer's drug, from $BIIB and EisaiAccording to MarketWatch, The FDA approved the Alzheimer's drug Legembi from Eisai and Biogen A quick look at the daily charts for $BIIB shows that it's already trading on or above major moving averages (ie. 9,21,50 SMA's). Also, seeing as this is a nice, green day for the SPY and BIIB has been beaten down recently, it's a nice long option for medium term traders and investors in general. If I were to go long, a nice R:R profit target would be the top of the Bollinger bands with a stop loss below the "fast" moving average in use. Good luck.
NASDAQ:BIIBLong
by Razak_Yorou
$BIIB: Update, get long!I think it warrants making a new publication here, $BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by $LLY's drug 'Donanemab'. I was long $LLY and have been trading in and out of $BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my $LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors $BIIB, so I'm only long Biogen currently. Best of luck! Cheers, Ivan.
NASDAQ:BIIBLong
by IvanLabrie